PEPCID for oral suspension is indicated for the short-term treatment of gastroesophageal reflux disease (GERD), active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer disease.
Gastroesophageal reflux disease is a digestive condition in which acid or bile enters the esophagus, resulting in a variety of uncomfortable symptoms. Some of the most common symptoms of GERD include heartburn, regurgitation, chest pain, cough, and difficulty swallowing. If GERD is not treated, it can cause severe damage to the esophagus.
A duodenal ulcer is a break in the lining of the duodenum (upper part of the small intestine) that may result in extreme pain associated with heartburn, stomach pain, weight gain, and a burning sensation in the back of the throat.
PEPCID relieves symptoms of these conditions by inhibiting gastric secretions. In clinical trials, PEPCID showed significant improvement in treating symptoms of duodenal ulcer, gastric ulcer, and GERD.
Important Safety Information about PEPCID
PEPCID® (famotidine) for Oral Suspension is indicated for the short-term treatment of gastroesophageal reflux disease (GERD), active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer disease. Side effects reported in >1% of patients in clinical trials were headache 4.7%, diarrhea 1.7%, dizziness 1.3%, and constipation 1.2%. Care should be taken in dose selection for patients with moderate or severe renal impairment. Pepcid is contraindicated in patients who are hypersensitive to any component of the product or to any other H2-receptor antagonist.
Consult with your physician to see if this product is right for you.
The information contained on this page is intended for US residents, healthcare providers, and pharmacists only.
For product information, adverse event reports, and product complaint reports please call:
Salix Product Information Call Center